Clinical Trial Detail

NCT ID NCT03541902
Title Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

chromophobe renal cell carcinoma

renal cell carcinoma

papillary renal cell carcinoma

Therapies

Cabozantinib

Sunitinib

Age Groups: adult senior

No variant requirements are available.